Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and …
…, P Goldstraw, M Hatton, P Hopwood, C Manegold… - The Lancet, 2007 - thelancet.com
Background Although surgery offers the best chance of cure for patients with non-small cell
lung cancer (NSCLC), the overall 5-year survival rate is modest, and improvements are …
lung cancer (NSCLC), the overall 5-year survival rate is modest, and improvements are …
[HTML][HTML] The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC
C Manegold, AMC Dingemans, JE Gray… - Journal of Thoracic …, 2017 - Elsevier
Over the past few years, there have been considerable advances in the treatments available
to patients with metastatic or locally advanced NSCLC, particularly those who have …
to patients with metastatic or locally advanced NSCLC, particularly those who have …
Treatment of advanced non–small-cell lung cancer in the elderly: Results of an international expert panel
…, K Kelly, T Le Chevalier, C Manegold… - Journal of Clinical …, 2005 - ascopubs.org
The best treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC)
is still debated. To guide clinical management of these patients and suggest the priorities for …
is still debated. To guide clinical management of these patients and suggest the priorities for …
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
…, S Emri, C Manegold, C Niyikiza… - Journal of clinical …, 2023 - ingentaconnect.com
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy
with a median survival time of 6 to 9 months, have previously responded poorly to …
with a median survival time of 6 to 9 months, have previously responded poorly to …
[PDF][PDF] Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung …
…, J Vansteenkiste, C Manegold… - Journal of clinical …, 2008 - journals.viamedica.pl
Cel. Cisplatyna z gemcytabiną jest standardowym leczeniem I linii chorych na zaawansowanego
niedrobnokomórkowego raka płuca (NSCLC). Badania kliniczne II fazy wykazały …
niedrobnokomórkowego raka płuca (NSCLC). Badania kliniczne II fazy wykazały …
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL
…, J Mezger, V Archer, N Moore, C Manegold - Journal of Clinical …, 2009 - ascopubs.org
Purpose Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor,
improves survival when combined with carboplatin/paclitaxel for advanced nonsquamous …
improves survival when combined with carboplatin/paclitaxel for advanced nonsquamous …
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2
…, JH Schiller, RB Natale, V Miller, C Manegold… - Journal of Clinical …, 2004 - iris.unito.it
PURPOSE: Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington,
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, may …
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
G Giaccone, RS Herbst, C Manegold… - Journal of Clinical …, 2004 - iris.unito.it
PURPOSE: The purpose of this study was to determine whether the addition of the epidermal
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839; AstraZeneca, …
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
V Trillet-Lenoir, J Green, C Manegold… - European Journal of …, 1993 - Elsevier
The aim of this study was to determine the usefulness of recombinant human granulocyte
colony stimulating factor (r-metHuG-CSF) following conventional chemotherapy for small cell …
colony stimulating factor (r-metHuG-CSF) following conventional chemotherapy for small cell …
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non–small-cell lung cancer
…, U Gatzemeier, K Mattson, C Manegold… - Journal of clinical …, 2000 - ascopubs.org
PURPOSE: The Hoosier Oncology Group has previously reported the results of its phase II
trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients …
trial of the combination of cisplatin plus gemcitabine. In that study of 27 assessable patients …